Redefining medical treatment in the management of unstable angina.

[1]  E. Antman,et al.  Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. , 1999, Circulation.

[2]  E. Antman,et al.  Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. , 1999, Circulation.

[3]  F. Ragmin.  Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study , 1999, The Lancet.

[4]  R. Califf,et al.  Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience. , 1999, Circulation.

[5]  C. Heeschen,et al.  Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. , 1999, The New England journal of medicine.

[6]  A. Mattioli,et al.  Organization to Assess Strategies for Ischemic Syndrome (OASIS-2) Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on preventing death, myocardial infarction, refractory angina and revascularization procedures in patients with acute myocardial ischemia without ST eleva , 1999 .

[7]  L. Wallentin,et al.  Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study , 1999 .

[8]  K. Karsch,et al.  Confronting the challenge of acute ischaemic coronary syndromes : proceedings of two satellite symposia to the XXth Congress of the European Society of Cardiology, Vienna, Austria, August, 1998 , 1999 .

[9]  E. Braunwald,et al.  Unstable angina: an etiologic approach to management. , 1998, Circulation.

[10]  R. Califf,et al.  Acute Coronary Syndromes in the GUSTO-IIb Trial Prognostic Insights and Impact of Recurrent Ischemia , 1998 .

[11]  K. Lee,et al.  Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. The GUSTO-IIa Investigators. , 1998, Circulation.

[12]  L. Wallentin,et al.  The FRISC experience with troponin T. Use as decision tool and comparison with other prognostic markers. , 1998, European heart journal.

[13]  J. Hirsh.  Low-molecular-weight heparin : A review of the results of recent studies of the treatment of venous thromboembolism and unstable angina. , 1998, Circulation.

[14]  E. Topol,et al.  Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial. , 1998, Circulation.

[15]  E. Braunwald,et al.  Invasive versus conservative strategies in unstable angina and non\NQ-wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 trial ☆ , 1998 .

[16]  S. Yusuf,et al.  Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation , 1998, The Lancet.

[17]  E. Vicaut,et al.  Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial. , 1998, Circulation.

[18]  T. Investigators.  Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. , 1998, Lancet.

[19]  E. Topol.  Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade , 1998, The Lancet.

[20]  R. Kleiger,et al.  Correction: Outcomes in Patients with Acute Non-Q-Wave Myocardial Infarction Randomly Assigned to an Invasive as Compared with a Conservative Management Strategy. , 1998, The New England journal of medicine.

[21]  D. Waters,et al.  Prognostic role of troponin T versus troponin I in unstable angina pectoris for cardiac events with meta-analysis comparing published studies. , 1998, The American journal of cardiology.

[22]  M. Simoons,et al.  Unstable angina: good long-term outcome after a complicated early course. , 1998, Journal of the American College of Cardiology.

[23]  E. Antman,et al.  C-Reactive Protein Is a Potent Predictor of Mortality Independently of and in Combination With Troponin T in Acute Coronary Syndromes: A TIMI 11A Substudy , 1998 .

[24]  D. Huse,et al.  Direct medical costs of coronary artery disease in the United States. , 1998, The American journal of cardiology.

[25]  R. Califf,et al.  Cardiac troponin T and cardiac troponin I: relative values in short-term risk stratification of patients with acute coronary syndromes , 1998 .

[26]  E. Braunwald,et al.  Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction. , 1998, Circulation.

[27]  Marc Cohen,et al.  One Year Follow-up of the ESSENCE Trial (enoxaparin Versus Heparin in Unstable Angina and Non-Q-Wave Myocardial Infarction) , 1998 .

[28]  R. Giugliano,et al.  Troponin I levels in unstable angina/non-Q wave myocardial infarction patients treated with tirofiban, a glycoprotein IIb/IIIa antagonist , 1998 .

[29]  E. Antman,et al.  Time to positivity of a rapid bedside assay for cardiac-specific troponin T predicts prognosis in acute coronary syndromes: a Thrombolysis in Myocardial Infarction (TIMI) 11A substudy. , 1998, Journal of the American College of Cardiology.

[30]  E. Topol.  Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence. , 1998, Circulation.

[31]  B. Coller,et al.  Monitoring platelet GP IIb/IIIa antagonist therapy. , 1998, Circulation.

[32]  R. Norris,et al.  The clinical course of patients with acute myocardial infarction who are unsuitable for thrombolytic therapy because of the presenting electrocardiogram. UK Heart Attack Study Investigators. , 1998, Coronary artery disease.

[33]  S. Snapinn,et al.  Improved long-term clinical outcomes in unstable angina-patients undergoing coronary angioplasty following therapy with tirofiban and heparin , 1998 .

[34]  P. Deedwania,et al.  Sustained platelet GP IIb/IIIa blockade with oral orbofiban: interim phamacodynamic results of the SOAR study , 1998 .

[35]  P. Deedwania,et al.  Sustained platelet GP IIb/IIIa blockade with oral orbofiban: interim safety and tolerability results of the SOAR study , 1998 .

[36]  C. Heeschen,et al.  Value of troponins in predicting therapeutic efficacy of abciximab in patients with unstable angina , 1998 .

[37]  A. Siegbahn,et al.  Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. , 1997, Circulation.

[38]  C. Heeschen,et al.  Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. , 1997, The New England journal of medicine.

[39]  H. Weisman,et al.  Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy. , 1997, Circulation.

[40]  D. Ardissino,et al.  C-reactive protein elevation and early outcome in patients with unstable angina pectoris. , 1997, The American journal of cardiology.

[41]  J. Weitz.  Low-molecular-weight heparins. , 1997, The New England journal of medicine.

[42]  T. Investigators.  Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. , 1997, Circulation.

[43]  R. Califf,et al.  A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. , 1997 .

[44]  H. Origasa,et al.  Predictive Validity of the Braunwald Classification of Unstable Angina for Angiographic Findings, Short-Term Prognoses, and Treatment Selection , 1997, Angiology.

[45]  Epilog Investigators,et al.  Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. , 1997, The New England journal of medicine.

[46]  Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II.  Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II , 1997, The Lancet.

[47]  Stgrp Capture,et al.  Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study , 1997, The Lancet.

[48]  B. Coller.  Perspectives Series: Cell Adhesion in Vascular Biology Platelet Gpiib/iiia Antagonists: the First Anti-integrin Receptor Therapeutics , 2022 .

[49]  N. Rao,et al.  7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[50]  S Wallenstein,et al.  Correlation of angiographic morphology and clinical presentation in unstable angina. , 1997, Journal of the American College of Cardiology.

[51]  S. Thompson,et al.  Production of C-reactive protein and risk of coronary events in stable and unstable angina , 1997, The Lancet.

[52]  L. Klein,et al.  Comparison of heparin therapy for < or = 48 hours to > 48 hours in unstable angina pectoris. , 1997, The American journal of cardiology.

[53]  F. Harrell,et al.  Cardiac Troponin T Levels for Risk Stratification in Acute Myocardial Ischemia , 1996 .

[54]  D Wybenga,et al.  Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. , 1996, The New England journal of medicine.

[55]  F. Werf.  Cardiac Troponins in Acute Coronary Syndromes , 1996 .

[56]  L. Wallentin,et al.  Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease. The FRISC study group. , 1996, Circulation.

[57]  E. Topol,et al.  Antiplatelet and anticoagulant use after myocardial infarction , 1996, Clinical cardiology.

[58]  W. Weaver,et al.  Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. , 1996, Journal of the American College of Cardiology.

[59]  E. Arbustini,et al.  Correlation between clinical and morphologic findings in unstable angina. , 1996, American Journal of Cardiology.

[60]  K. Wiklund,et al.  Low-molecular-weight heparin during instability in coronary artery disease , 1996 .

[61]  M. Simoons.  A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. , 1996, The New England journal of medicine.

[62]  R. Califf,et al.  Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. , 1995, American Journal of Cardiology.

[63]  D. Waters,et al.  Prognostic value of cardiac troponin T in unstable angina pectoris. , 1995, The American journal of cardiology.

[64]  B. Nafe,et al.  Clinical predictors of unstable coronary lesion morphology. , 1995, European heart journal.

[65]  W. O’Neill,et al.  A new clinical classification for hospital prognosis of unstable angina pectoris. , 1995, The American journal of cardiology.

[66]  P. Bossuyt,et al.  Incidence and follow-up of Braunwald subgroups in unstable angina pectoris. , 1995, Journal of the American College of Cardiology.

[67]  K. Thygesen,et al.  Independent prognostic value of serum creatine kinase isoenzyme MB mass, cardiac troponin T and myosin light chain levels in suspected acute myocardial infarction. Analysis of 28 months of follow-up in 196 patients. , 1995, Journal of the American College of Cardiology.

[68]  L. Klein,et al.  Risk stratification in unstable angina. Prospective validation of the Braunwald classification. , 1995, JAMA.

[69]  R. Califf,et al.  Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. , 1994, Circulation.

[70]  J. Mcmanus.  Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: Results of the TIMI IIIB trial: The TIMI IIIB Investigators Circulation 89:1545–1556 Apr 1994 , 1994 .

[71]  A. Rebuzzi,et al.  The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. , 1994, The New England journal of medicine.

[72]  Daniel B. Mark,et al.  Diagnosing and managing unstable angina. Agency for Health Care Policy and Research. , 1994, Circulation.

[73]  Epic Investigators,et al.  Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. , 1994, The New England journal of medicine.

[74]  L. Wilkins.  Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. , 1994, Circulation.

[75]  S. Cobbe.  Thrombolysis in myocardial infarction , 1994, BMJ.

[76]  Eric J. Topol,et al.  Diagnosing and Managing Unstable Angina, Quick Reference Guide for Clinicians , 1994 .

[77]  J. Ravkilde,et al.  Diagnostic performance and prognostic value of serum troponin T in suspected acute myocardial infarction. , 1993, Scandinavian journal of clinical and laboratory investigation.

[78]  E. Braunwald,et al.  Relation between clinical presentation and angiographic findings in unstable angina pectoris, and comparison with that in stable angina. , 1993, The American journal of cardiology.

[79]  J. Dinerman,et al.  Unstable angina: Relationship of clinical presentation, coronary artery pathology, and clinical outcome , 1993, Clinical cardiology.

[80]  J. Ladenson,et al.  Development of monoclonal antibodies for an assay of cardiac troponin-I and preliminary results in suspected cases of myocardial infarction. , 1992, Clinical chemistry.

[81]  H. Katus,et al.  The prognostic value of serum troponin T in unstable angina. , 1992, The New England journal of medicine.

[82]  D. Waters,et al.  Reactivation of unstable angina after the discontinuation of heparin. , 1992, The New England journal of medicine.

[83]  J. Hampton,et al.  Predictors of risk in patients with unstable angina admitted to a district general hospital. , 1992, British heart journal.

[84]  A. Remppis,et al.  Development and in vitro characterization of a new immunoassay of cardiac troponin T. , 1992, Clinical chemistry.

[85]  W. Weintraub,et al.  Elevation of C-reactive protein in "active" coronary artery disease. , 1990, The American journal of cardiology.

[86]  Conti Cr.  Pathophysiology and management of unstable angina. , 1989 .

[87]  I. Wilcox,et al.  Risk of adverse outcome in patients admitted to the coronary care unit with suspected unstable angina pectoris. , 1989, The American journal of cardiology.

[88]  E. Braunwald,et al.  Unstable angina. A classification. , 1989, Circulation.

[89]  F. Harrell,et al.  Importance of clinical measures of ischemia in the prognosis of patients with documented coronary artery disease. , 1988, Journal of the American College of Cardiology.

[90]  A. Maseri,et al.  Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. , 1982, British heart journal.